Genomics and personalized medicine: CHRNA5- CHRNA3-CHRNB4 and smoking cessation treatment

Journal of Food and Drug Analysis

Volumn 21, Issue 4 SUPPL., 2013, Pages

  Chen, Li Shiun ^a   Bierut, Laura J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Personalized medicine; Pharmacogenetics; Smoking cessation

Indexed keywords

NICOTINIC RECEPTOR;

CONFERENCE PAPER; GENE CLUSTER; GENETIC RISK; GENETIC VARIABILITY; GENETICS; GENOMICS; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTION; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

EID: 84897023922     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2013.09.041     Document Type: Conference Paper

References (31)

1. Breslau N, Johnson EO, Hiripi E, et al. Nicotine dependence in the United States: Prevalence, trends, and smoking persistence.[see comment]. Arch Gen Psychiatry 2001;58:810-6.
2. Breslau N, Johnson EO. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am J Public Health 2000;90:1122-7.
3. Baker TB, Piper ME, McCarthy DE, et al. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine Tob Res 2007;9(Suppl. 4):S555-70.
4. Hendricks PS, Prochaska JJ, Humfleet GL, et al. Evaluating the validities of different DSM-IV-based conceptual constructs of tobacco dependence. Addiction 2008;103:1215-23.
5. Kozlowski LT, Porter CQ, Orleans CT, et al. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend 1994;34:211-6.
6. West R. Defining and assessing nicotine dependence in humans. In: Bock G, Goode J, editors. Understanding nicotine and tobacco addiction. Novartis Foundation Symposium, No 275. Chichester: Wiley; 2005. p. 36-58.
7. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature 2011;470:204-13.
8. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2013. http://dx.doi.org/10. 1200/JCO.2013.49.3122.
9. Liu JZ, Tozzi F, Waterworth DM, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 2010;42:436-40.
10. Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: A meta-analysis and comparison with lung cancer and COPD. PLoS Genet 2010;6:e1001053.
11. Tobacco and Genetics Consortium (TAG). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010;42:441-7.
12. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010;42:448-53.
13. Weiss RB, Baker TB, Cannon DS, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 2008;4:e1000125.
14. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008;165:1163-71.
15. Kuryatov A, Berrettini W, Lindstrom J. Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2) alpha5 AChR function. Mol Pharmacol 2011;79:119-25.
16. Wang JC, Cruchaga C, Saccone NL, et al. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet 2009;18:3125-35.
17. Baker TB, Weiss RB, Bolt D, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res 2009;11:785-96.
18. Freathy RM, Ring SM, Shields B, et al. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet 2009;18:2922-7.
19. Munafo MR, Johnstone EC, Walther D, et al. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 2011;13:982-8.
20. Sarginson JE, Killen JD, Lazzeroni LC, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3- B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2011;156B(3):275-84.
21. King DP, Paciga S, Pickering E, et al. Smoking cessation pharmacogenetics: Analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012;37:641-50.
22. Breitling LP, Twardella D, Hoffmann MM, et al. Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics 2010;11:527-36.
23. Conti DV, Lee W, Li D, et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008;17:2834-48.
24. Uhl GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: Convergent genome-wide association study results. Arch Gen Psychiatry 2008;65:683-93.
25. Chen LS, Baker TB, Piper ME, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry 2012;169:735-42.
26. Berrettini WH, Wileyto EP, Epstein L, et al. Catechol-Omethyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007;61:111-8.
27. Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 2013;23:94-103.
28. Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statintreated patients with coronary artery disease. Circ J 2009;73:1283-90.
29. Suissa S. Number needed to treat in COPD: Exacerbations versus pneumonias. Thorax 2013;68:540-3.
30. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: A meta-analysis of individual patient data. Lancet 2008;371:908-14.
31. Rutter JL. Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J 2006;8:E174-84.